This is the authors' abstract. We don't add key points for this paper.
We argue that there are four actions Australia should take to advance equitable global access to COVID-19 vaccines: produce, donate, redistribute and fund more COVID-19 vaccines for LICs; support a broad and workable TRIPS Waiver; invest in building production capacity in LMICs; and impose conditions on public funding for R&D for COVID-19 health products and technologies to ensure know-how is shared and pricing is fair.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Gleeson et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: